BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
Status:
Completed
Trial end date:
2017-03-21
Target enrollment:
Participant gender:
Summary
This is a phase 1/2 clinical trial with the goal of determining whether the addition of the
investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free
survival in patients with BRAFV600E/K mutant melanoma.